BLR Bio’s BLR-200 shows promise in systemic sclerosis models

May 4, 2026

BLR Bio LLC has presented new data highlighting the potential of BLR-200 for the treatment of systemic sclerosis (scleroderma). The company also presented data on its research on CCN proteins as potential noninvasive biomarkers for systemic sclerosis.

BioWorld Science Dermatologic

Today's news in brief

BioWorld

BioWorld briefs for May 4, 2026.

Axsome’s Auvelity cleared for large Alzheimer’s agitation market

BioWorld

Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...

Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

BioWorld

Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...

Unique trial strategy muddies the ODAC waters for camizestrant

BioWorld

Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...

Sonire starts US study of cancer HIFU after $18M series A

BioWorld

Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...